Allergy Therapeutics (AGY) — Cash Flow-to-Debt Ratio
Allergy Therapeutics (AGY) has a Cash Flow-to-Debt Ratio of -0.22x as of June 2025, meaning its operating cash flow of GBX-21.09 Million could theoretically repay 0% of its total liabilities (GBX95.74 Million) in one year. Check AGY cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Allergy Therapeutics Cash Flow-to-Debt Ratio (2002–2025)
Historical debt coverage capacity for Allergy Therapeutics across 24 annual periods. Also explore AGY total asset value for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Allergy Therapeutics (2002–2025)
Year-by-year debt coverage analysis for Allergy Therapeutics. For market capitalisation and broader financial context, see market value of Allergy Therapeutics.
| Year | CF-to-Debt Ratio | Operating CF (GBX) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.30x | GBX-28.72 Million | GBX95.74 Million | ▲ +43.0% |
| 2024 | -0.53x | GBX-32.14 Million | GBX61.12 Million | ▼ -10.1% |
| 2023 | -0.48x | GBX-30.92 Million | GBX64.70 Million | ▼ -19.1% |
| 2022 | -0.40x | GBX-14.11 Million | GBX35.18 Million | ▼ -286.3% |
| 2021 | 0.22x | GBX8.52 Million | GBX39.55 Million | ▼ -25.6% |
| 2020 | 0.29x | GBX12.28 Million | GBX42.44 Million | ▲ +59.8% |
| 2019 | 0.18x | GBX5.60 Million | GBX30.94 Million | ▲ +233.2% |
| 2018 | -0.14x | GBX-3.80 Million | GBX27.98 Million | ▼ -2177.6% |
| 2017 | 0.01x | GBX178.00K | GBX27.22 Million | ▲ +101.5% |
| 2016 | -0.45x | GBX-11.84 Million | GBX26.36 Million | ▼ -333.5% |
| 2015 | 0.19x | GBX3.12 Million | GBX16.23 Million | ▲ +18.0% |
| 2014 | 0.16x | GBX2.17 Million | GBX13.32 Million | ▼ -4.1% |
| 2013 | 0.17x | GBX2.43 Million | GBX14.29 Million | ▼ -22.2% |
| 2012 | 0.22x | GBX2.88 Million | GBX13.16 Million | ▲ +407.5% |
| 2011 | -0.07x | GBX-2.03 Million | GBX28.48 Million | ▼ -205.5% |
| 2010 | 0.07x | GBX1.70 Million | GBX25.23 Million | ▲ +793.8% |
| 2009 | -0.01x | GBX-440.00K | GBX45.25 Million | ▲ +98.3% |
| 2008 | -0.56x | GBX-19.32 Million | GBX34.47 Million | ▲ +54.3% |
| 2007 | -1.23x | GBX-18.88 Million | GBX15.40 Million | ▲ +21.7% |
| 2006 | -1.56x | GBX-8.10 Million | GBX5.18 Million | ▼ -17953.9% |
| 2005 | -0.01x | GBX-57.00K | GBX6.58 Million | ▼ -101.9% |
| 2004 | 0.46x | GBX1.91 Million | GBX4.16 Million | ▲ +22.6% |
| 2003 | 0.37x | GBX2.10 Million | GBX5.60 Million | ▲ +362.1% |
| 2002 | -0.14x | GBX-2.01 Million | GBX14.07 Million | — |